Expression and distribution of S-100, CD83, and costimulatory molecules (CD80 and CD86) in tissues of thyroid papillary carcinoma

Cancer Investigation

Volumn 29, Issue 4, 2011, Pages 286-292

  Xu, Wen Can ^a   Li, Zheng Bing ^a   Chen, Yong Ru ^a   Li, Xi Tao ^a   Huang, Jie Xiong ^a   Li, Yu Guang ^a   Chen, Shen Ren ^b  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

CD80; CD83; CD86; S 100 protein; Thyroid papillary carcinoma (TPC)

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; PROTEIN S 100;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; THYROID ADENOMA; THYROID FOLLICULAR ADENOMA; THYROID PAPILLARY CARCINOMA;

ADENOMA; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CASE-CONTROL STUDIES; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; S100 PROTEINS; THYROID NEOPLASMS; TIME FACTORS; TUMOR ESCAPE;

EID: 79953798036     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.568561     Document Type: Article

References (48)

1. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 2007;14:719-729. (Pubitemid 46175318)
2. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009;16:17-44.
3. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003;19:225-234. (Pubitemid 37011337)
4. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-411. (Pubitemid 29180578)
5. Kadowaki N, Antonenko S, Ho S, Rissoan MC, Soumelis V, Porcelli SA, Lanier LL, Liu YJ. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J Exp Med 2001;193:1221-1226. (Pubitemid 32488374)
6. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, Gray GS, Nadler LM. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-911. doi: 10.1126. (Pubitemid 24014081)
7. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of cell costimulation. Annu Rev Immunol 1996;14:233-258.
8. Tang KF, Chan SH, Loh KS, Chong SM,Wang D, Yeoh KH, Hu H. Increased production of interferon-gamma by tumour infiltrating T lymphocytes in nasopharyngeal carcinoma: indicative of an activated status. Cancer Lett 1999;140:93-98. (Pubitemid 29251318)
9. Yang WF, Yu JM, Zuo WS, Wang SZ. Expression of CD80, CD86, TGF-beta1 and IL-10 mRNA in the esophageal carcinoma. Zhonghua Zhong Liu Za Zhi (Chinese Journal of Oncology) 2006;28(10):762-765.
10. Chen S, Luo YP, Zhang JK, Yang W, Zhen ZC, Chen LX, Zhang W. Study on immune function of dendritic cells in patients with esophageal carcinoma.World J Gastroenterol 2002;8:203-207.
11. Tirapu I, Huarte E, Guiducci C, Arina A, ZaratieauiM,Murillo O, GonzalezA,BerasainC,Berraondo P, Fortes P, Prieto J, Colombo MP, Chen L, Melero I. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res 2006;66(4):2442-2450.
12. Fujiwara K, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Uemura M, Nakamura S, Sato S, Hanafusa T, Yumoto Y, Naito I, Shiratori Y. Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma 2004;19(10):1121-1127.
13. Kilicarslan B, Pesterelli EH, Oren N Sarqin FC, Karpuzoqlu G. Epithelial membrane antigen and S-100 protein expression in benign andmalignant papillary thyroid neoplasms. Adv Clin Path 2000;4(4):155-158.
14. Li YQ, Zeng BH. In vitro culture and anti-cancer immunity of dendritic cells. Chin J of Cancer Prev & Treat 2001;8(1):78-80.
15. Chen S, Akbar SM, Tanimoto K, Ninomiya T, Iuchi H, Michitaka K, Horiike N, Onji M. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett 2000;148(1):49-57. (Pubitemid 30012128)
16. Xu WC, Chen SR, Huang JX, Zheng ZC, Chen LX, Lin JJ, Li YG. Expression and distribution of S-100 protein, CD83 and apoptosis-related proteins (Fas, FasL and Bcl-2) in the thyroid tissues of autoimmune thyroid diseases. Eur J Histochem 2007;51(4):291-300.
17. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998;4:63-68. (Pubitemid 28139143)
18. Vieweg J, Jackson A. Modulation of antitumor responses by dendritic cells. Springer Semin. Immunopathol 2005;26:329-341.
19. Rasaiyaah J, Yong K, KatzDR, KellamP, and Chain BM.Dendritic cells and myeloid leukaemias: plasticity and commitment in cell differentiation. Br J Haematol 2007;138:281-290. (Pubitemid 47035382)
20. Demetris AJ, Sever C, Kakizoe S,Oguma S, Starzl TE, Jaffe R. S100 protein-positive dendritic cells in primary biliary cirrhosis and other chronic inflammatory liver diseases, relevance to pathogenesis. Am J Pathol 1998;134:741-747.
21. Ishigami S,Aikou T, Natsugoe S, Hokita S, Iwashige H, Tokushige M, Sonoda S. Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology 1998;55:65-69. (Pubitemid 128707626)
22. Pfragner R, Skofitsch G, Hoger H, Jech M, Rinner B, Siegl V, Niederle B, Gnant M, Friedl J, Stift A. Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination. Anticancer Res 2005;25(6B):4225-4230. (Pubitemid 41665208)
23. Schott M, Scherbaum WA. Immunotherapy and gene therapy of thyroid cancer. Minerva Endocrinol 2004;29(4):175-187.
24. Woods GM, Doherty KV, Malley RC, Rist MJ, Muller HK. Carcinogen-modified dendritic cells induce immunosuppression by incomplete T-cell activation resulting from impaired antigen uptake and reduced CD86 expression. Immunology 2000;99:16-22. (Pubitemid 30062933)
25. Zhang JK, Sun JL, Chen HB, Zeng Y and Qu YJ. Influence of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor on anti-hepatoma activities of human dendritic cells.World J Gastroenterol 2000;6:718-720.
26. Zhang JK, Li J, Chen HB, Sun JL,Qu YJ, Lu JJ. Antitumor activities of human dendritic cells derived from peripheral and cord blood. World J Gastroenterol 2002;8:87-90. (Pubitemid 34149767)
27. Yamakawa M, Kato H, Takagi S, Karube Y, Seki K, Imai Y. Dendritic cells in various human thyroid diseases. In Vivo 1993;7(3):249-256. (Pubitemid 23205702)
28. Stulk J, Osterreicher J, Koupilova K, Knizek J, Macela A, bures J, Jand?k P, Langr F, Dedic K, Jungblut PR.The analysis of S100 A9 and S100 A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S-100 A9 and S-100 A8 positive cells underlie and invade tumor mass. Electrophoresis 1999;20(4-5):1047-1054. (Pubitemid 29222467)
29. Yinemura Y, Endou Y, Kimura K, Fushida S, Bandou E, Taniguchi K, Kinoshita K, Ninomiya I, Sugiyama K, Heizmann CW, Schafer BW, Sasaki T. Inverse expression of S100 A4 and Ecadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 2000;6(11):4234-4242.
30. Rudland PS, Platt Higgins A, Renshaw C, West CR, Winstanley JHR, Robertson L, Barraclough R. Prognostic significance of the metastasis-inducing protein S100 A4(p9Ka) in human breast cancer. Cancer Res 2000;60(6):1595-1603. (Pubitemid 30183430)
31. Rustandi RR, Baldisseri DM, Weber DJ. Structure of the negative regulatory domain of p53 bound to S100B (betabeta). Nat Struct Biol 2000;7(7):570-574. (Pubitemid 30445914)
32. Xu W, Chen S, Huang J, Zhang Z, Chen L, Zhang W. The expression and distribution of S-100 protein and CD 83 in thyroid tissues of autoimmune thyroid diseases. Cell Mol Immunol 2004;1(5):378-382.
33. Pesce G, Fiorino N, Riccio AM, Montagna P, Torre G, Salmaso C, Altrinetti V, Bagnasco M. Different intrathyroid expression of intercellular adhesion molecule-1 (ICAM-1) in Hashimoto's thyroiditis and Graves' disease: analysis at mRNA level and association with B7. 1 costimulatory molecule. J Endocrinol Invest 2002;25(3):289-295. (Pubitemid 34295886)
34. Chen SR, Lou YP, Zhang JK, Yang W, Zhen ZC, Chen LX, Zhang W. The study on immune function of dendritic cells in patients with esophageal carcinoma. World J Gastroenterol 2004;10(7):934-939. (Pubitemid 38461370)
35. + murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumor and host cells. Immunology 2000;101:541-547. (Pubitemid 32001469)
36. Zai SH, Liu JB, Zhu P andWang YH. The expression of CD80 and CD86 in hepatocarcinoma and cirrhosis tissues. J Fourth Mil Med Univ 2001;21:26-27.
37. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human bood dendritic cell subsets by IFNs. Immunology 2001;104:2961-2969. (Pubitemid 33117291)
38. Xing LH,Wang FS, Liu MX, Zhu CL. Dendritic cells and liver diseases. Shijie Huaren Xiaohua Zazhi 2000;8:1276-1279.
39. Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev 1999;13:51-64. (Pubitemid 29178531)
40. Li X, Takahashi Y, Sakamoto K, Nakashima T. Expression of dendritic cell phenotypic antigens in cervical lymph nodes of patients with hypopharyngeal and laryngeal carcinoma. J Laryngol Otol Suppl 2009;31:5-10.
41. Kara PP, Ayhan A, Caner B, Gultekin M, Ugur O, Bozkurt MF, Usubutun A, Uner A. Analysis of dendritic cells in sentinel lymph nodes of patients with endometrial and patients with cervical cancers. Int J Gynecol Cancer 2009;19(7):1239-1243.
42. Fiumara A, Belfiore A, Russo G, Salomone E, Santonocito GM, Ippolito O, Vigneri R, Gangemi P. In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer. J Clin Endocrinol Metab 1997;82:1615-1620. (Pubitemid 27200444)
43. Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S, Uchino S, Toda M, Sasaki A, Daa T, Nakayama I. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma.Thyroid 1998;8:197-202. (Pubitemid 28145182)
44. Yan XM, Guo J, Pichurin P, Tanaka K, Jaume JC, Rapoport B, McLachlan SM Cytokines, IgG subclasses and costimulation in a mouse model of thyroid autoimmunity induced by injection of fibroblasts co-expressing MHC class II and thyroid autoantigens. Clin Exp Immunol 2000;122:170-179.
45. Maile R, Elsegood KA, Harding TC, Uney JB, Stewart CE, Banting G, Dayan CM. Effective formation of major histocompatibility complex class II-peptide complexes from endogenous antigen by thyroid epithelial cells. Immunology 2000;99:367-374. (Pubitemid 30137701)
46. Thomas GR, Wen J. Endogenous expression of CD80 costimulatory molecules facilitates in vivo tumor regression of oral squamous carcinoma. Anticancer Res 2006;26:4093-4101. (Pubitemid 46039581)
47. Yang G, Hellstrom KE, Hellstrom I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995;154:2794-2800.
48. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-1102. (Pubitemid 23016545)